AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 687,000 shares, an increase of 317.6% from the June 30th total of 164,500 shares. Currently, 3.5% of the shares of the company are sold short. Based on an average trading volume of 2,750,000 shares, the short-interest ratio is currently 0.2 days.
A hedge fund recently raised its stake in AEterna Zentaris stock. Morgan Stanley raised its holdings in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 11.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 857,534 shares of the biopharmaceutical company’s stock after purchasing an additional 89,792 shares during the period. Morgan Stanley owned 3.65% of AEterna Zentaris worth $439,000 at the end of the most recent reporting period. 5.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of AEZS stock opened at $0.47 on Friday. The firm has a market cap of $19.31 million, a price-to-earnings ratio of -23.46 and a beta of 1.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.35 and a current ratio of 3.46. AEterna Zentaris has a 52 week low of $0.37 and a 52 week high of $2.57. The firm’s 50-day simple moving average is $0.68 and its two-hundred day simple moving average is $0.85.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, missing the consensus estimate of $1.68 by ($1.64). The business had revenue of $1.09 million for the quarter.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: How Do Mutual Funds Work?
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.